c
x
chart
exchange
Terminal
Flow
Screener
Markets
Trends
Premium
Alerts
EST
UTC-5 New York
Blue Chip
Log in
Sign up
Starling Oncology expects $650M-$660M revenue and $4M-$6M adjusted EBITDA in 2026 while targeting 100% capitated revenue growth in 2027
Seeking Alpha | Nov 6, 2026 11:55 AM EST
Read original article